Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLK2 | Q86UE8 | 1/20 | 0.56 |
| ▸ | SMYD3 | Q9H7B4 | 7/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.50 |
| ▸ | PGR | P06401 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | RARA | P10276 | 1/20 | 0.50 |
| ▸ | RARB | P10826 | 1/20 | 0.50 |
| ▸ | RARG | P13631 | 1/20 | 0.50 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.50 |
| ▸ | BLVRB | P30043 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7717889 | 0.92 | CRBN (0.60) | TLK2SMYD3HDAC3MEN1CYP26A1 | |
| SCHEMBL5842454 | 0.90 | TLK2 (0.57) | TLK2SMYD3HDAC3LRRK2GAA | |
| SCHEMBL26547572 | 0.87 | SMYD3 (0.56) | TLK2SMYD3HDAC3CRBNLRRK2 | |
| SCHEMBL1663776 | 0.86 | TLK2 (0.53) | TLK2SMYD3HDAC3CRBNLRRK2 | |
| SCHEMBL4405727 | 0.86 | CRBN (0.65) | TLK2SMYD3HDAC3RARARARB | |
| SCHEMBL23175704 | 0.85 | LMNA (0.57) | TLK2SMYD3HDAC3CRBNLRRK2 | |
| SCHEMBL29899570 | 0.85 | LMNA (0.57) | TLK2SMYD3HDAC3CRBNLRRK2 | |
| SCHEMBL26547582 | 0.84 | CA1 (0.58) | TLK2SMYD3HDAC3MEN1KMT2A | |
| SCHEMBL578342 | 0.83 | SMYD3 (0.61) | TLK2SMYD3HDAC3CRBNLRRK2 | |
| SCHEMBL29642948 | 0.83 | SMYD3 (0.61) | TLK2SMYD3HDAC3CRBNLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2020408-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | Sugen, Inc. (US) | 2009-02-04 | — | — | EP | disclosed |
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-7189721-B2 | Bicyclic protein kinase inhibitors | SUGEN INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189721-B2 | Bicyclic protein kinase inhibitors | SUGEN INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189721-B2 | Bicyclic protein kinase inhibitors | SUGEN INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-7119090-B2 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| US-6878733-B1 | Formulations for pharmaceutical agents ionizable as free acids or free bases | SUGEN, INC. (US) | 2005-04-12 | — | — | US | disclosed |
| US-20040106630-A1 | Bicyclic protein kinase inhibitors | SUGEN, INC. | 2004-06-03 | — | — | US | disclosed |
| US-20040106618-A1 | Bicyclic protein kinase inhibitors | SUGEN, INC. | 2004-06-03 | — | — | US | disclosed |
| US-6350754-B2 | ANTICARCINOGENIC AGENTS | SUGEN, INC. | 2002-02-26 | — | — | US | disclosed |
| US-20010056094-A1 | Anticarcinogenic agents | TANG PENG CHO (US) | 2001-12-27 | — | — | US | disclosed |
| US-6316429-B1 | ENZYME INHIBITORS MODULATE THE ACTIVITY OF PROTEIN KINASES AND THEREFORE ARE EXPECTED TO BE USEFUL IN THE PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED CELLULAR DISORDERS SUCH AS CANCER. | SUGEN, INC. | 2001-11-13 | — | — | US | disclosed |
| US-6313158-B1 | THERAPY AND PROPHYLAXIS OF CANCER | SUGEN, INC. | 2001-11-06 | — | — | US | disclosed |
| EP-1082305-A4 | PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS | SUGEN INC (US) | 2001-09-26 | — | — | EP | disclosed |
| EP-1082305-A1 | PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS | Sugen, Inc. (US) | 2001-03-14 | — | — | EP | disclosed |
| US-6051593-A | USEFUL IN THE PREVENTION AND TREATMENT OF PROTEIN TYROSINE KINASE RELATED CELLULAR DISORDERS SUCH AS CANCER | SUGEN, INC. (US) | 2000-04-18 | — | — | US | disclosed |
| EP-0984930-A1 | 2-INDOLINONE DERIVATIVES AS MODULATORS OF PROTEIN KINASE ACTIVITY | Sugen, Inc. (US) | 2000-03-15 | — | — | EP | disclosed |
| WO-1999061422-A1 | PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS | SUGEN, INC. (US) | 1999-12-02 | — | — | WO | disclosed |
| WO-1998050356-A1 | 2-INDOLINONE DERIVATIVES AS MODULATORS OF PROTEIN KINASE ACTIVITY | SUGEN, INC. (US) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056094-A1 | Anticarcinogenic agents | GSTK1, CDC42BPG, GLS | TLK2 761/4885SMYD3 4192/4885HDAC3 1218/4885 |
| US-20040106618-A1 | Bicyclic protein kinase inhibitors | MAP3K20, MAP4K3, MAP4K2 | TLK2 326/4885SMYD3 4044/4885HDAC3 1062/4885 |
| US-20040106630-A1 | Bicyclic protein kinase inhibitors | MAP3K20, MAP4K3, MAP4K2 | TLK2 326/4885SMYD3 4044/4885HDAC3 1062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.